Evidence map›Paper›PMID 41263027›Full record

ArticleRedox report : communications in free radical research2025

Drynachromoside A from

Huankai Yao, Jindong Li, Ruiqing Wu, Dan Du, Fengwei Ai, Yan Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox report : communications in free radical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huankai YaoDepartment of Microbial and Biochemical Pharmacy, School of Pharmacy & Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.
Jindong LiTaizhou School of Clinical Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, People's Republic of China.
Ruiqing WuDepartment of Microbial and Biochemical Pharmacy, School of Pharmacy & Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.
Dan DuDepartment of Microbial and Biochemical Pharmacy, School of Pharmacy & Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.
Fengwei AiDepartment of Microbial and Biochemical Pharmacy, School of Pharmacy & Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.
Yan LiDepartment of Microbial and Biochemical Pharmacy, School of Pharmacy & Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.ORCID 0000-0001-5723-6936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetic nephropathy (DN) is the most common complication of diabetes mellitus. It has shown that the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) could attenuate DN. To identifiy novel Nrf2 activators targeting DN, we explored drynachromoside A (DCSA) from

methodsTo determine the effects of DCSA, the proliferation of mesangial cells induced by high glucose was evaluated. And the renal function of

resultsDCSA inhibited the proliferation of mesangial cells resulting from high glucose and improved renal function in

conclusionDCSA identified in

Indexed as

Diabetic NephropathiesNF-E2-Related Factor 2Oxidative StressAnimalsCell ProliferationFibrosisKelch-Like ECH-Associated Protein 1MaleMesangial CellsMiceMice, Inbred C57BLKeap1 protein, mouseKelch-Like ECH-Associated Protein 1Nfe2l2 protein, mouseNF-E2-Related Factor 2db/db micediabetic nephropathyDrynachromoside ADrynaria fortuneifibrosismesangial cellNrf2oxidative stress

Identifiers

PMID41263027
PMCPMC12636548

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.